ScreenerHero

BCLI Brainstorm Cell Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · brainstorm-cell.com
0.8700USD-3.33%Mkt Cap: 9.60M $P/E: —

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn propriet…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap9.60M USD
Enterprise Value12.72M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.31M USD
Revenue/Share—
Last Price0.8700 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS10501E2019
Valuation
P/E (Trailing)—
P/E (Forward)-1.01
PEG—
EV/EBITDA-1.30
EV/Revenue—
P/S—
P/B-0.98
EPS (TTM)-0.93
EPS (Forward)-1.02
52W Range
0.460033% of range1.690
52W High1.690 USD
52W Low0.4600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.22%
ROA-1008.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.97M USD
CapEx (TTM)—
FCF Margin—
FCF Yield13.56%
Net Debt1.35M USD
Net Debt/EBITDA-0.14
Balance Sheet
Debt/Equity-0.02
Current Ratio0.03
Quick Ratio0.01
Book Value/Sh-1.05 USD
Cash/Share0.0020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 1, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.03M
Float10.10M
Insiders8.68%
Institutions0.00%
Short Interest
Short Ratio1.3d
Short % Float6.05%
Short % Out.5.60%
Shares Short566.39K
Short (prev mo.)463.31K
Technical
SMA 500.9844 (-11.6%)
SMA 2000.8157 (+6.7%)
Beta0.26
S&P 52W Chg16.45%
Avg Vol (30d)13.13K
Avg Vol (10d)9.79K
Technical Indicators
RSI (14)42.7
MACD0.0055
MACD Signal0.0315
MACD Hist.-0.0260
BB Upper1.270 USD
BB Middle1.046 USD
BB Lower0.8209 USD
BB Width42.97%
ATR (14)0.1205 USD
Vol Ratio (20d)0.66x